sorafenib
Tislelizumab Vies for First-Line Designation in Treatment of Advanced HCC
The checkpoint inhibitor tislelizumab might reasonably be considered a better choice for hepatocellular carcinoma ...
OCTOBER 20, 2023
Better Outcomes, No Reduced Safety When Sorafenib Is Preceded by Stereotactic Body RT for HCC
Administering stereotactic body radiation therapy before sorafenib significantly improves overall and ...
JUNE 6, 2023
Tremelimumab/Durvalumab Combo Promising for Unresectable HCC
Combining a single priming dose of tremelimumab and durvalumab significantly improved overall survival in the ...
FEBRUARY 11, 2022
Load more